ImmunoCellular Therapeutics (IMUC) a development stage company, focuses on developing and commercializing therapeutics to fight cancer using the immune system.

The company’s product candidate portfolio includes peptide based cellular immunotherapies targeting cancer stem cells, cellular immunotherapies targeting cancer antigens, and monoclonal antibodies to diagnose and treat various cancers.

Its lead product candidate is a dendritic cell based vaccine, which has completed Phase I clinical trial for the treatment of glioblastoma multiforme, a type of brain tumor. ImmunoCellular Therapeutics has a research agreement with Antitope, Ltd. for the humanization of monoclonal antibodies.

The company is based in Woodland Hills, California.

Information provided by Capital IQ.

http://www.imuc.com

Track Two - 11:30 am